There were considerable side-effects to the therapy, though most of them were reversible. Around 83 percent of the patients experienced cytokine release syndrome, a common complication following T-cell therapy with symptoms such as fever, nausea, chills, and abnormally low blood pressure. Unfortunately, two patients were hospitalized and one patient died during the course of the treatment.
To check that those in remission remained that way, the team analyzed samples from 12 of the patients' bone marrow four weeks after treatment. Of those, seven had no malignant copies of cancer.
The study is still in its early stages, but shows considerable promise. The side effects are a legitimate concern, though the potential of remission is a huge boon.
Just last week, the FDA panel recommended the approval of Novartis’ CAR-T therapy for B-cell acute lymphoblastic leukemia in children and young adults. The FDA is expected to make their final decision by October 3, 2017.